Quantifying the evolution and impact of antimalarial drug resistance: Drug use, spread of resistance, and drug failure over a 12-Year period in papua new guinea

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 435-443

  Nsanzabana, Christian ^a,b,e   Hastings, Lan M ^d   Marfurt, Jutta ^a   Müller, Ivo ^c   Baea, Kay ^c   Rare, Lawrenpe ^c   Schapira, Allan ^a   Felger, Ingrid ^a   Betschart, Bruno ^b   Smith, Thomas A ^a   Beck, Hans Peter ^a   Genton, Blaise ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF NEUCHÂTEL   (Switzerland)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; CHLOROQUINE; FANSIDAR; ANTIMALARIAL AGENT; PROTOZOAL PROTEIN;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HUMAN; NONHUMAN; PAPUA NEW GUINEA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MALARIA FALCIPARUM; METABOLISM; PARASITOLOGY; PLASMODIUM FALCIPARUM; TIME;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; HAPLOTYPES; HUMANS; MALARIA, FALCIPARUM; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOZOAN PROTEINS; TIME FACTORS;

EID: 75649126925     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649784     Document Type: Article

References (49)

1. 1. Talisuna AO, Bioland P, D'Alessandro U. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004; 17(l):235-254. (Pubitemid 38120936)
2. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176:1590-1596.
3. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6(4):861-871.
4. 4. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AE Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403(6772):906-909. (Pubitemid 30130994)
5. Cortese JF, Caraballo A, Contreras CE, Plowe CV. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 2002; 186(7):999-1006.
6. Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418(6895);320-323.
7. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305(5687);1124.
8. Hastings IM, Smith TA. MalHaploFreq; a computer programme for estimating malaria haplotype frequencies from blood samples. Malar J 2008; 7(l);130.
9. Genton B, al-Yaman F, Beck HP, et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasital 1995; 89(4):359-376.
10. Genton B, al-Yaman F, Beck HP, et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med Parasital 1995; 89(4):377-390.
11. Alpers MP, al-Yaman F, Beck HP, et al. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies. PNG Med J 1992; 35(4) :285-297.
12. 12. Müller I, Smith T, Mellor S, Rare L, Genton B. The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Int J Epidemiol 1998; 27(5) :878-884. (Pubitemid 28504978)
13. Papua New Guinea Department of Health. Standard treatment for common illnesses of children in Papua New Guinea. 6th ed. Port Moresby, Papua New Guinea: Department of Health, 1993.
14. 14. Crameri A, Marfurt J, Mugittu K, et al. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol 2007; 45(11) :3685-3691. (Pubitemid 350156867)
15. 15. Falk N, Maire N, Sama W, et al. Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 2006; 74(6) :944-950. (Pubitemid 351627397)
16. Schneider AG, Premji Z, Felger I, et al. A point mutation in codon 76 of pfcrt of P. falciparum is positively selected for by chloroquine treatment in Tanzania. Infect Genet Evol 2002; 1(3):183-189.
17. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical recipes in C: the art of scientific computing. 3rd ed. Cambridge, UK: Cambridge University Press, 2007.
18. 18. Anderson TJ, Roper C. The origins and spread of antimalarial drug resistance; lessons for policy makers. Acta Trop 2005; 94(3):269-280. (Pubitemid 40720332)
19. Noranate N, Durand R, Tall A, et al. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS ONE 2007; 2(l) :e l39.
20. 20. Hastings IM, Watkins WM. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 2006; 22 (2):71-77. (Pubitemid 43145866)
21. Laufer MK, Plowe CV. Cotrimoxazole prophylaxis and malaria in Africa; h7ave the important questions been answered? Am J Trop Med Hyg 2006; 75:373-374.
22. Spencer M. The history of malaria control in the southwest Pacific region, with particular reference to Papua New Guinea and the Solomon Islands. PNG Med J 1992; 35:33-66.
23. Watkins WM, Sibley CH, Hastings IM. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am J Trop Med Hyg 2005; 72(2) :163-173.
24. Ord R, Alexander N, Dunyo S, et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis 2007; 196:16131619.
25. Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. New Eng J Med 2006; 355 (19):1959-1966.
26. Babiker H, Hastings IM, Swedberg G. Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug deployment policies. Expert Rev Anti Infect Ther 2009; 7:581-593.
27. Hastings IM, Donnelly MJ. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat 2005; 8:43-50.
28. Walliker D, Hunt P, Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop 2005; 94 (3):251-259.
29. Fisher RA. The wave of advance of advantageous genes. Ann Eugen 1937; 7:355-369.
30. Hastings IM. Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. Trop Med Int Health 2006; 11(8):1206-1217.
31. Hastings IM. The origins of antimalarial drug resistance. Trends Parasitol 2004; 20(11):512-518.
32. 32. Hastings IM. A model for the origins and spread of drug resistant malaria. Parasitology 1997; 115:133-141. (Pubitemid 27334567)
33. 33. Nair S, Williams JT, Brockman A, et al. A selective sweep driven by pyrimethamine treatment in SE Asian malaria parasites. Mol Biol Evol 2003; 20:1526-1536. (Pubitemid 37082588)
34. 34. Müller I, Bockarie M, Alpers M, Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003; 19(6):253-259. (Pubitemid 36638726)
35. Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. PNG Med J 2005; 48(3-4):141-150.
36. 36. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360(9350): 2031-2038. (Pubitemid 36026582)
37. 37. Rwagacondo CE, Niyitegeka F, Sarushi J, et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg 2003; 68(6) :743-747. (Pubitemid 38235107)
38. Marfurt J, Müeller I, Sie A, et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 2007; 77(5):947-954.
39. 39. Marfurt J, Müller I, Sie A, et al. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulfadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malar J 2008; 7:61. (Pubitemid 351678131)
40. Mita T, Kaneko A, Hwaihwanje I, et al. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea. Infect Genet Evol 2006; 6(6):447-452.
41. Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of chloroquinesensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003; 187(12):1870-1875.
42. Plowe CV, Kublin JG, Dzinjalamala FK, et al. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ 2004; 328(7439):545.
43. Erratum in: BMJ 2004; 328(7442):762.
44. Babiker HA, Satti G, Ferguson H, Bayoumi R, Walliker D. Drug resistant Plasmodium falciparum in an area of seasonal transmission. Acta Trop 2005; 94(3):260-268.
45. Quaye I, Sibley CH. Molecular data on Plasmodium falciparum chloroquine and antifolates resistance: a public health tool. Trends Parasitol 2002; 18(4): 184-186.
46. Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol 2003; 206(Pt 21) :3745-3752.
47. 46. Plowe CV, Roper C, Barnwell JW, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J 2007; 6:121. (Pubitemid 47566322)
48. Hastings IM, Korenromp EL, Bioland PB. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infect Dis 2007; 7(11):739-748.
49. 48. Mbacham W, Njikam N. Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy. Med Trop 2007; 67(2):183-187. (Pubitemid 350157219)